Cantor Fitzgerald Believes GW Pharma (GWPH) Still Has Room to Grow


In a report released today, Elemer Piros from Cantor Fitzgerald reiterated a Buy rating on GW Pharma (GWPH), with a price target of $196. The company’s shares closed on Friday at $169.32, close to its 52-week high of $182.23.

Piros observed:

“: We are reiterating our Overweight rating on GW Pharmaceuticals and raising our 12-month price target to $196/ADS from $193/ ADS following the announced sale of Voucher (PRV). As a reminder, GW Pharmaceuticals was awarded the PRV following the EPIDIOLEX approval last year. The recipient of the PRV was not announced in the press release.”

According to TipRanks.com, Piros is a 1-star analyst with an average return of -1.9% and a 44.6% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Proteostasis Therapeutics Inc.

GW Pharma has an analyst consensus of Strong Buy, with a price target consensus of $178.43, representing a 5.4% upside. In a report issued on March 5, Piper Jaffray also reiterated a Buy rating on the stock with a $185 price target.

See today’s analyst top recommended stocks >>

Based on GW Pharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $71.31 million. In comparison, last year the company had a GAAP net loss of $62.29 million.

Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It offers its lead cannabinoid product, Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD) focusing on the treatment of seizures associated with tuberous sclerosis complex.

Read More on GWPH:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts